Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
A New Drug for HF? DEFINE-HF Bolsters Dapagliflozin Cardio CredOn the heels of the DAPA-HF outcomes trial, DEFINE-HF shows adding the SGLT-2 inhibitor to standard meds improved other endpoints
heart failure patients care about, whether or not they had diabetes.
Medscape Medical News, Sep 17, 2019
Shock and Awe: ARNI for Acute HF May Be Safely Started in ICUSome patients in cardiogenic shock may transition from IV vasoactive agents to sacubitril/valsartan without going hypotensive,
suggests a small case series; PA-pressure guidance was crucial.
Medscape Medical News, Sep 17, 2019
No SGLT-2 Inhibitor Echo Benefit in Preserved-EF HF, DiabetesAny reverse-remodeling effects from the drugs may not apply to people with diabetes and heart failure with preserved ejection
fraction, a group that hasn't been well studied, a small study suggests.
